MHR
ALXN

Matthew Hamilton Rosenberg’s Alexion Pharmaceuticals ALXN Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-92
Closed -$17K – 699
2021
Q2 		$17K Hold
92
– – 0.01% 477
2021
Q1 		$14K Hold
92
– – 0.01% 464
2020
Q4 		$14K Hold
92
– – 0.01% 445
2020
Q3 		$11K Hold
92
– – 0.01% 449
2020
Q2 		$10K Buy
+92
New +$9.77K 0.01% 485

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Matthew Hamilton Rosenberg's ALXN Position: Q3 2021 in Review

Matthew Hamilton Rosenberg sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 92 shares — an estimated $17K sold.

Matthew Hamilton Rosenberg first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $17K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Matthew Hamilton Rosenberg reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Matthew Hamilton Rosenberg sold 92 Alexion Pharmaceuticals shares in Q3 2021, an estimated $17K.
  • Matthew Hamilton Rosenberg first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Matthew Hamilton Rosenberg's Alexion Pharmaceuticals position peaked at $17K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Matthew Hamilton Rosenberg's 13F filing for Q3 2021, filed 12 Oct 2021.